A meeting of the National Drug Scheduling Advisory Committee (NDSAC) was held on June 15, 2020 and June 18, 2020 with the following interim recommendations made:
- Acetaminophen and ibuprofen in oral, fixed-dose combinations, in package sizes containing 20,000 mg or less of acetaminophen and 6,000 mg or less of ibuprofen, be granted Schedule III status and
- Acetaminophen and ibuprofen in oral, fixed-dose combinations, in package sizes containing either more than 20,000 mg of acetaminophen or more than 6,000 mg of ibuprofen, be granted Schedule II status
Any objections to these interim recommendations must be received by the NAPRA office by end of day July 26, 2020. Questions or comments should be directed to the Manager, Professional and Regulatory Affairs, Sarah Marshall via email at firstname.lastname@example.org.